<DOC>
	<DOCNO>NCT01785329</DOCNO>
	<brief_summary>Primary Objective : To assess relative bioavailability single subcutaneous dose alirocumab SAR236553 ( REGN727 ) administer 3 different injection sit healthy subject . Secondary Objectives : - To assess pharmacodynamic effect single subcutaneous dose alirocumab SAR236553 ( REGN727 ) serum low-density lipoprotein cholesterol lipids apolipoproteins . - To assess safety single subcutaneous dose alirocumab SAR236553 ( REGN727 ) . - To assess immunogenicity single subcutaneous dose alirocumab SAR236553 ( REGN727 ) .</brief_summary>
	<brief_title>Pharmacokinetic Alirocumab SAR236553 ( REGN727 ) Administered Subcutaneously 3 Different Injection Sites Healthy Subjects</brief_title>
	<detailed_description>Total duration study per subject 15 week .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Healthy subject . Exclusion criterion : Healthy subject history presence clinically relevant illness . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>